Chabiotech Co.,Ltd.

KOSDAQ:A085660 Stock Report

Market Cap: ₩831.8b

ChabiotechLtd Past Earnings Performance

Past criteria checks 0/6

ChabiotechLtd's earnings have been declining at an average annual rate of -43.9%, while the Healthcare industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 13% per year.

Key information

-43.9%

Earnings growth rate

-43.7%

EPS growth rate

Healthcare Industry Growth34.2%
Revenue growth rate13.0%
Return on equity-1.0%
Net Margin-0.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Nov 12
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

Mar 01
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

Jan 25
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Dec 21
The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Revenue & Expenses Breakdown

How ChabiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A085660 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,009,799-2,602246,13415,493
30 Jun 24974,803-23,278239,14615,773
31 Mar 24949,922-27,916239,14314,838
31 Dec 23953,951-8,431234,34014,614
30 Sep 23942,431-31,870236,33614,455
30 Jun 23921,073-39,266228,95113,999
31 Mar 23892,981-37,037221,26414,586
31 Dec 22844,583-47,543214,93714,359
30 Sep 22808,777-4,922197,99613,787
30 Jun 22779,374602182,06913,369
31 Mar 22747,666-21,366183,23412,791
31 Dec 21727,476-13,968173,41413,050
30 Sep 21704,072-26,755167,57013,401
30 Jun 21694,812-31,561171,88113,895
31 Mar 21677,277-16,194162,58813,453
31 Dec 20664,717-18,658161,03013,457
30 Sep 20655,853-7,667152,99411,890
30 Jun 20590,893-8,520150,87212,206
31 Mar 20565,52949,125146,29212,234
31 Dec 19534,61246,375144,87711,328
30 Sep 19500,91046,386148,32810,419
30 Jun 19515,23251,595142,6568,408
31 Mar 19502,20119,231141,1647,464
31 Dec 18488,60024,698128,3416,771
30 Sep 18502,3601,516123,7336,202
30 Jun 18467,869-12,462118,9577,391
31 Mar 18435,256-37,872107,6898,690
31 Dec 17417,460-45,585112,5149,462
30 Sep 17402,155-20,436105,05415,492
30 Jun 17416,750-9,272103,46713,124
31 Mar 17434,6691,02499,21710,609
31 Dec 16449,26111,44898,6978,876
30 Sep 16428,117-6,336143,8943,503
30 Jun 16423,770-8,274126,7773,446
31 Mar 16410,812-10,394111,8443,448
31 Dec 15393,782-14,95695,6043,373
30 Sep 15424,0741,80532,3162,298
30 Jun 15386,370-56229,1242,085
31 Mar 15361,625-2,25733,9881,746
31 Dec 14345,345-4,72135,4171,569
30 Sep 14298,626-12,15742,7111,203
30 Jun 14323,263-5,31248,8461,126
31 Mar 14370,7494,71250,281958
31 Dec 13386,83511,30853,8521,018

Quality Earnings: A085660 is currently unprofitable.

Growing Profit Margin: A085660 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A085660 is unprofitable, and losses have increased over the past 5 years at a rate of 43.9% per year.

Accelerating Growth: Unable to compare A085660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A085660 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.6%).


Return on Equity

High ROE: A085660 has a negative Return on Equity (-0.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 00:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chabiotech Co.,Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Jung-In LeeKorea Investment & Securities Co., Ltd.